February 11, 2019 08:35 AM EST
Pharma

Ab­b­Vie jumps in­to the fren­zied race for a BC­MA/CD3 bis­pe­cif­ic tar­get­ing mul­ti­ple myelo­ma. Teneo­bio who?

John Carroll

Editor & Founder

Every­body wants a BC­MA bis­pe­cif­ic. And Ab­b­Vie just front­ed $90 mil­lion to get one from a lit­tle-known Sil­i­con Val­ley biotech called Teneo­bio.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Cash, chips and tal­ent: In­side Nvidi­a's plan to dom­i­nate biotech's AI rev­o­lu­tion

A ma­jor­i­ty of phar­ma and biotech com­pa­nies pro­hib­it Chat­G­PT use, sur­vey finds

GSK un­veils long-term Shin­grix da­ta as shin­gles com­pe­ti­tion heats up

Sen­ate bill tar­get­ing WuXi won't af­fect fed­er­al spend­ing, CBO says

Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

Re­gen­eron en­ters ven­ture in­vest­ing with $500M, poach­es se­nior part­ner from ARCH

A service from the Financial Times